A Single Arm, Open-Label Pilot Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) Stage IB to IV

Conditions

Non-Hodgkin's Lymphoma

Phase Pilot

What is the purpose of this trial?

Cutaneous T cell lymphoma (CTCL) is an incurable skin-homing T cell non-Hodgkin lymphoma (NHL) that may commonly have blood/leukemic and lymph node involvement.  Advanced stages of CTCL are more likely to have blood/leukemic and lymph node involvement and show resistance to standard therapy.  There are currently only two oral agents approved for the treatment of CTCL: bexarotene and vorinostat.  Venetoclax is a newly approved oral agent for the treatment of CLL.  Venetoclax has also been shown to be especially potent against NHL and AML cell lines expressing high levels of Bcl-2.6, 7  We have recently revealed that the malignant cells isolated from a cohort of CTCL patients exhibit extreme sensitivity to venetoclax by cell viability assays, with EC50 doses as low as 1-3 nM, and this sensitivity correlated with Bcl-2 expression. Thus, venetoclax is a promising candidate novel therapy for CTCL.

  • Trial with
    AbbVie Inc.
  • Start Date
    03/31/2019
  • End Date
    02/27/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Kacie R. Carlson

  • Last Updated
    04/24/2019
  • Study HIC
    #2000022803